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Abstract Matrix metalloproteinases (MMPs) and adamalysins
(ADAMs) cleave many extracellular proteins, including matrix,
growth factors, and receptors. We pro¢led the RNA levels of
every MMP, several ADAMs, and inhibitors of metalloprotei-
nases (TIMPs and RECK) in numerous mouse tissues during
development and in the uterus during pregnancy. Observations
include: most secreted MMPs are expressed at low to undetect-
able levels in tissues, whereas membrane-bound MMPs,
ADAMs and inhibitors are abundant; almost every proteinase
and inhibitor is present in the uterus or placenta at some time
during gestation; the mouse collagenases mColA and mColB
are found exclusively in the uterus and testis ; and each tissue
has its unique signature of proteinase and inhibitor expression.
. 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Proteases are enzymes that can hydrolyze peptide bonds of
proteins, and there are over 550 members in each of the
mouse and human genomes [1]. These enzymes are classi¢ed
according to the composition of their catalytic site as aspartic,
cysteine, metallo, serine, or threonine proteases, and are fur-
ther divided into clans and families based on structural sim-
ilarity [2]. The family of matrix metalloproteinases (MMPs)
consists of 24 human or 23 mouse zinc-dependent endopepti-
dases that collectively can degrade all proteinaceous compo-
nents of the extracellular matrix, thereby facilitating tissue
remodeling and cell migration. These enzymes can also cleave
and activate growth factors and cytokines, shed their recep-
tors from the cell surface, and disrupt the interaction of
growth factors and receptors with associated proteins [3,4].
Through these varied actions, MMPs have a profound e¡ect
on the pericellular environment, promoting or disrupting tis-
sue integrity.
Sub-classi¢cation of the MMPs was originally based on
their matrix substrate, but now MMPs have a number desig-
nation (MMP-1^28), based on the order in which they were
identi¢ed, and are classi¢ed according to protein structure [5].
MMP-7 and human MMP-26 have the minimal domain struc-
ture that is shared by all MMPs: an amino-terminal signal
sequence (pre), a propeptide domain, and a catalytic domain
containing the zinc binding site. The remaining MMPs con-
tain at least one of a hemopexin-like domain, a ¢bronectin-
like domain, a recognition motif for furin-like serine pro-
teases, a vitronectin-like insert, a transmembrane domain, or
a glycosylphosphatidylinositol (GPI) anchor.
Another family of metalloproteinases (MPs) is the 32 dis-
integrins and metalloproteinases, or adamalysins (ADAMs),
proteins containing extracellular disintegrin, metalloprotei-
nase, and cysteine-rich, EGF-like domains, followed (in
most) by transmembrane and cytoplasmic regions. Many
ADAMs are found only in the testes, where they potentially
play roles in spermatogenesis and subsequently in fertilization,
and only about half the family have the HEXXHXXGXXH
catalytic core required for MP activity. Only a minority of
ADAMs have both a broad tissue distribution and the ca-
pacity to be proteolytically active [6].
Activity of both the MMPs and ADAMs is inhibited prin-
cipally by the four tissue inhibitors of metalloproteinase
(TIMPs). Inhibition results from the TIMP protein binding
to the active site of the MMPs in a 1:1 stoichiometric ratio.
For the most part, each of the TIMPs can non-selectively bind
to all MMPs, with one exception being the inability of TIMP-
1 to inhibit e¡ectively several matrix-bound MMPs (MMP-14,
-15, -16, -24) [7]. In addition, the membrane-anchored glyco-
protein RECK can inhibit MMP-9 [8], MMP-2 and MMP-14
[9], and mice with a RECK null mutation die in utero due to
defects in collagen formation and vascular development [9].
The balance or imbalance of MPs with inhibitor levels is
therefore a potential predictor of extracellular matrix (ECM)
production and/or degradation.
MMPs, ADAMs and TIMPs are implicated as regulators of
many physiological and pathological processes, including, but
by no means limited to, tissue development, placenta forma-
tion, ovulation, wound healing, cancer progression, and neu-
ral degeneration [2,3,5,10]. Historically, only a small number
of MMPs have been studied in each of these processes, in
part because of the relative ease of measurement for these
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MMPs but also because many MPs have only recently been
identi¢ed.
We used hybridization-probe-based quantitative real-time
polymerase chain reaction (qPCR) to determine mRNA levels
of a large number of MPs and inhibitors. With this technique,
during each PCR cycle a gene-speci¢c £uorogenic probe hy-
bridizes to its target cDNA and is digested by endonuclease
activity of the polymerase generating a £uorescent signal; the
amount of £uorescence is proportional to the amount of
cDNA ampli¢ed. The cycle number (termed cycle threshold,
or CT) at which ampli¢cation entered the exponential phase
was determined and this number used as an indicator of the
amount of mRNA in each tissue, i.e. a lower CT indicates a
higher quantity of starting RNA. This study represents the
¢rst comprehensive and simultaneous analysis of every mouse
MMP, TIMP, several proteolytic ADAMs and RECK, in a
variety of mouse tissues throughout development.
2. Materials and methods
2.1. Tissue collection and RNA isolation
Tissues were collected from CD-1 mice (Charles River, Lachine,
QC, Canada), with the exception of the lung tissue, which was col-
lected from C57/Black6 mice (Charles River). Female mice, 7^8 weeks
of age, were paired with males to generate pregnant animals for col-
lection of staged embryonic and postnatal tissues with noon of the
day of the vaginal plug being designated day 0.5 post coitum (pc).
Female animals were killed at various days pc to recover embryos,
uteri and placentas, while newborn mice were killed at various days
post partum. A range of tissues from multiple embryos and newborn
mice were dissected and pooled, including brain, heart, lung, skeletal
muscle, kidney and liver. In addition, testis, spleen, thymus and adre-
nal gland were collected from newborn mice. Tissues were frozen on
dry ice and stored at 370‡C. All animals were cared for and killed in
accordance with guidelines of the Canadian Council for Animal Care.
2.2. RNA isolation, reverse transcription and qPCR
Total RNA was extracted using the single-step guanidinium isothio-
cyanate method, as described previously [11], followed by incubation
with 20 U of DNase I, RNase-free (Roche, Lewes, UK) for 10 min at
37‡C and heat inactivation at 70‡C for 15 min. One microgram of
total RNA was reverse transcribed using 2 Wg random hexamers
(Amersham Biosciences, Amersham, UK) and 200 U of Superscript
II reverse transcriptase (Invitrogen Life Technologies, Paisley, UK),
according to the supplier’s instructions. qPCR reactions were done on
the ABI Prism 7700 (Applied Biosystems, Warrington, UK) according
to previously described methods [11], with each reaction containing
5 ng of reverse-transcribed RNA in 25 Wl.
Sequences for most primers and probes are described elsewhere [12],
but we also designed and used primers and probes for MMP-27,
ADAM-10, -12, -15, -17, -19, -28, -33, RECK, and a di¡erent set of
mColA, mColB, and MMP-10 primers and probes (Table 1); these
were designed using Primer Express 1.0 software (Applied Biosys-
tems). 18S rRNA (primers and probes from Applied Biosystems)
was used as an endogenous control to account for di¡erences in the
extraction and reverse transcription of total RNA.
Table 1
Primer and probe sequences of genes analyzed by qPCR
Gene Primer/probe Sequence
mColA Forward CGTGGACCAACAGCAGTGAA
Reverse GAGTGAGCCCAAGGGAGTGA
Probe TCAACTTGTTCTATGTTACGGCTCATGAACTGG
mColB Forward TGGACCGACAACAATGAGGAT
Reverse TGGGAGAGTCCAAGGGAGTG
Probe as mColA
MMP-10 Forward CCTGCTTTGTCCTTTGATTCAGT
Reverse CGGGATTCCAATGGGATCT
Probe TCCTATTCTTTAAAGACAGGTACTTCTGGCGCA
MMP-27 Forward AGGATAATAAAGTGCTTCCCAGGA
Reverse AAGAAATAGAGGAATCCATTATGTTGG
Probe TCGCCTCCGTGTGGATGCTGTC
ADAM10 Forward GTGCCAGTACAGGCTCTTTGC
Reverse CACAGTAGCCTCTGAAGTCATTACATG
Probe ACTATCACTCTGCAGCCGGGCTCTCC
ADAM12 Forward ATCAGTGTCTTCGGCGTTCA
Reverse GGCAATTCTTCCTGTTGTTACATACC
Probe CCATGCAGTGCCACGGCCG
ADAM15 Forward GACCACTCCACAAGCATCTTAGG
Reverse GGGAGAATCATGGTCCAAACC
Probe TGCCTCCTCGATTGCCCATGAATTG
ADAM17 Forward AAGTGCAAGGCTGGGAAATG
Reverse CACACGGGCCAGAAAGGTT
Probe CCTGCGCATGCATTGACACTGACAAC
ADAM19 Forward CGGGCCCACCTCGAA
Reverse CCGTTTCATTCTGCGAGGTT
Probe TGGGCCCTTCAGTTTACACATCAGACCA
ADAM28 Forward TACTGCTTGAAGGGCAAATGTC
Reverse TGTCCCACCTTCATTCTGCTT
Probe TCCAGGAACCAAGGTTGCAAATACATCATGTTAC
ADAM33 Forward CAGGCACTGTCAGAATGCTACCT
Reverse CTATTGCAAACCCCACCGTTA
Probe TGGAACGTTGCTTGACTGCCTGCC
RECK Forward GGCCTCACCGTGCACTTG
Reverse TGGAGGAACGCTTTGCAGTT
Probe CTGGACTAGACCCTGACCACCCACAACTG
Sequences for the genes not included in this table can be found in [12].
Sequences are shown in a 5P to 3P orientation; probes contain a carboxy£uorescein £uorescent reporter on the 5P end and a carboxytetra-
methylrhodamine quencher on the 3P end.
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2.3. Analysis
The CT at which ampli¢cation entered the exponential phase was
determined and this number was used as an indicator of the amount
of target RNA in each tissue, i.e. a lower CT indicated a higher
quantity of starting RNA.
3. Results and discussion
We utilized TaqMan0-based qPCR to pro¢le the RNA lev-
els of every mouse MMP and TIMP, and several proteolytic
ADAMs, in various mouse tissues during development. To
aid in the visual presentation of these data, results are shown
as the CT value, which provides an accurate approximation of
the level of expression of each gene. In previous reports we
Fig. 1. The relative mRNA levels for all mouse MMPs and TIMPs and several ADAMs in mouse tissues throughout development. Classi¢ca-
tion of expression levels was determined from the CT of each gene as either very high (CT9 25), high (CT = 26^30), moderate (CT = 31^35), low
(CT = 36^39), or not detected (CT = 40); see legend for color scheme.
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determined absolute transcript numbers for each gene, which
required synthesizing and quantifying RNA transcripts and
then making serial dilutions of its cDNA covering the range
of 108 to 101 transcripts [11,13]. However, we observed that
for di¡erent genes, when equal numbers of transcripts were
analyzed, the di¡erences in CT value were never greater than
¢ve. We therefore consider the CT value a reliable overall
indicator of relative RNA abundance.
Fig. 1 shows the results with MMPs organized by structural
similarity as opposed to numerical order. This highlights the
low abundance in non-reproductive tissues of MMP-7, the
simplest MMP in terms of domain structure, and all of the
simple hemopexin MMPs except MMP-19. However, many of
these genes, while expressed at relatively low levels in most
normal tissues, are elevated in the uterus and testes, and in
various pathologies [2,3,5,10]. There is complete absence of
expression for MMP-20 (enamelysin) in all tissues, although
this gene has only ever been detected in tooth pulp tissue and
odontoblasts [14,15]. Conversely there is essentially ubiquitous
and abundant expression of the gelatinases, the type I MT-
MMPs, most ADAMs, and the TIMPs. Substrates for the
MT-MMPs and ADAMs include other proteases, or growth
factors and associated proteins, and the presence of these
enzymes does not imply ECM degradation, but instead sup-
ports the suggestion by Pagenstecher et al. [16] that cells and
tissue are in an ‘alert state’ awaiting the availability of a sub-
strate.
This study represents the ¢rst extensive analysis of every
member of the MMP and TIMP family concurrently during
tissue development, although there have been numerous stud-
ies that have looked at one, or a few genes together, with the
majority of these having results in agreement with ours. When
mColA and mColB, the mouse orthologues of human MMP-
1, were identi¢ed, their expression was found only in the pla-
centa and absent in the embryo, kidney, ovary, and lung [17].
We further show that transcripts for these genes are also ab-
sent in the brain, heart, muscle, and liver, but are present at
abundant levels in the testes, a tissue not previously examined.
The mColA and mColB genes are present in mouse and rat
and presumably re£ect a recent duplication event during
mammalian evolution [1]. It is interesting therefore that the
expression of these two genes seems to be restricted exclu-
sively to reproductive tissues, whereas the distant human rel-
ative plays a more fundamental role in tissue remodeling pro-
cesses.
Pagenstecher et al. [16] used RNase protection assays to
simultaneously analyze nine MMPs and three TIMPs in adult
mouse brain, kidney, liver, and spleen. Like us, they detected
MT1-MMP (MMP-14), stromelysin-3 (MMP-11), and macro-
phage metalloelastase (MMP-12) mRNAs in all tissues, with
those for stromelysin-1 (MMP-3), stromelysin-2 (MMP-10),
matrilysin (MMP-7) and collagenase (MMP-13) absent in
all. Here, we further show that MMP-3, -7, and -10 tran-
scripts are absent in most tissues, but are present in reproduc-
tive tissues, in agreement with others [18,19]. However, in
contradiction to the Pagenstecher report, we detected MMP-
13 RNAs in most tissues, with the highest levels in the kidney.
It has previously been shown that gelatinase A (MMP-2) is
most abundantly expressed in kidney and spleen [16], while
another study showed it as highest in the lung, muscle and
kidney [20], in complete agreement with our data. We addi-
tionally show that MMP-2 mRNA is very abundant in the
heart, a tissue that was not included in the other studies.
Gelatinase B (MMP-9), on the other hand, is lowly expressed,
but its RNA is also present in all tissues.
Many of the transmembrane MMPs are highly expressed in
most tissues. When mouse MT1-MMP (MMP-14) was ¢rst
characterized, its RNA was most abundant in the placenta,
kidney, heart, and lung [21], as we show, while MT5-MMP
(MMP-24) was originally characterized as being predominant
in the brain and testes [22], and our data demonstrate that it is
weakly or not expressed in other tissues. There have not yet
been broad tissue pro¢les for the remaining MT-MMPs until
this study. MT2- and MT3-MMP (MMP-15 and -16) tran-
scripts, like MMP-14, are abundant and ubiquitous, while
transcripts of the two GPI-anchored MT-MMPs, MT4- and
MT6-MMP (MMP-17 and -25) are in all tissues, although at
lower levels. MMP-23, a type II transmembrane protein that
is soluble in its active form, is expressed in all tissues but at
the highest levels in the uterus, ovary, and kidney, in agree-
ment with others [23].
ADAMs are transmembrane MPs that are distinct from the
MMPs in that they also have an extracellular disintegrin do-
main and a cytoplasmic domain that can associate with intra-
cellular proteins. Five of the seven ADAMs that we pro¢led
are abundantly expressed in most tissues, and four of these,
ADAM12, ADAM19 [24], ADAM15 [25], and ADAM17 [26],
have been shown by others to have identical tissue distribu-
tion as ours. Our data also support the observations that
ADAM28 is expressed in only a few tissues, notably the epi-
didymis and the lung [27], and that ADAM33 is widely ex-
pressed [28].
The MP inhibitors were found in all tissues examined. Of
the four TIMPs, TIMP-2 is the most constitutively expressed
at high levels, while the other three have a more speci¢c pat-
tern of high expression. In fact, the expression patterns we
describe for all TIMPs are identical to previously published
patterns [29,30]. The constitutive and very abundant expres-
sion of at least one TIMP in every tissue may provide a
crucial checkpoint for tissue degradation. When the RECK
gene was ¢rst identi¢ed, it was observed to be expressed in
a wide variety of human tissues [8], and we show that its
transcripts are also present in a wide variety of mouse tissues,
though at most sites RECK is expressed at a lower level than
any of the four TIMPs. Interestingly, mice with a RECK null
mutation die in utero due to poor collagen formation and
vascular defects [9], whereas mice lacking TIMP-1, -2, or -3
are viable. Our results do not suggest a pattern of RECK
expression distinct from the TIMPs to explain this embryonic
lethality.
This study is also the ¢rst to describe the tissue distribution
of MMP-27 in any species. The primers and probe for this
gene were based on the predicted sequence for the Rattus
norvegicus MMP-27 sequence (GenBank accession number
XM235795) and have not been examined in the mouse. Using
this primer set we detected an amplicon that has a sequence
identical to a portion of the rat sequence. This transcript was
detected in most tissues, with the exception of the brain, with
highest expression in the liver. There have been no functional
studies done for this putative protein.
A notable ¢nding from this study is that the transcripts for
most MMPs, all ADAMs, and all TIMPs are present at some
time in the uterus, placenta, or decidua. This re£ects the ex-
tensive tissue generation and remodeling that occurs during
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placenta formation. Between days 5 and 10 pc ¢brillar colla-
gen and ¢bronectin are replaced by type IV collagen and
laminin, which is later degraded by the invading trophoblast
cells [31], while at parturition there is a massive breakdown in
the uterine ECM [32]. mColA and mColB transcripts are
present initially in the uterus (days 9.5^13.5 pc), with their
expression later changing to the placenta, while mRNA levels
for the other major collagenase, MMP-13, increases in the
placenta towards parturition. Another interesting observation
is the low expression of ADAM28 in the early uterus, with its
levels substantially elevated at day 17.5 pc, implicating this
enzyme as a putative mediator of parturition.
Each tissue exhibits unique patterns of MP and TIMP ex-
pression. In the brain, there are substantial gains in the levels
of MMP-24, ADAM33 and TIMP-4 transcripts from day 11.5
to postnatal day 28, and complete losses of MMP-3, MMP-7,
MMP-27, and ADAM28 RNAs. As neural development pro-
gresses, there is production of both ¢bronectin and laminin to
facilitate the migration of glial and neuronal cells [33,34]. It
may be that the presence of MMP-3, -7, -27 and ADAM28 at
early times limits matrix deposition, and their disappearance,
along with the increase in TIMP-4 expression, facilitates ma-
trix stability. On the other hand, the increase in MMP-24
expression may be associated with neurite extension and axo-
nal growth [35].
In the development of the heart, the prenatal stage is char-
acterized by myocyte proliferation while postnatally there is
myocyte hypertrophy and interstitial cell proliferation [36].
Growth of the myocytes is in part regulated by the presence
of collagen [37], and it is interesting to note that around the
time of parturition, there is an increase in the expression of
several MMPs, including MMP-2, -3, -12, -27, and -24, sug-
gesting a breakdown of ECM components leading to termi-
nation of myocyte growth stimuli.
Development of both the lung and kidney is characterized
by branching ^ the bronchioles in the lung, and the ureteric
bud in the kidney. Both the lung and kidney have high levels
of MMP-2, MMP-14, ADAM15, 17, 19, TIMP-2, and -3
RNAs throughout development, and both have an increase
in MMP-12 levels over time. However, in the lung, there is
a unique decrease in MMP-7 and increase in MMP-8 expres-
sion, while the kidney exhibits a decrease in MMP-8, -14, and
ADAM10, but an increase in MMP-21 and -25. Regulation of
MP activity is essential in branching morphogenesis as mice
with a null mutation in TIMP-3 show reduced branching of
bronchioles [38].
The liver and spleen are early sites of hematopoiesis in the
fetus, and both of these tissues have high mRNA levels of
MMP-14, -19, ADAM10, and TIMP-2. It should be noted
that in the liver there is a transient phase of high MMP ex-
pression from newborn to 7 days, with peaks in MMP-8, -14,
-27 and -28 RNA levels. These enzymes potentially mediate
the changes from a fetal ECM to an adult ECM and promote
liver development, since the fetal ECM inhibits growth of
hepatocytes [39].
Skeletal muscle development is principally characterized by
di¡erentiation and fusion of myoblast cells and three major
mediators of this process are meltrins K, L, and Q (ADAM12,
ADAM19, and ADAM9) [40]. In this study, RNA levels of
these ADAMs are lower in the muscle than in other tissues,
although this may be because the samples were from newborn
onward, after the time period of myogenesis. There is, how-
ever, elevated ADAM19 in the newborn and 3-day-old mice,
possibly representing the last stages of myogenesis.
In conclusion, this report demonstrates high RNA levels of
many MT-MMPs, ADAMs and TIMPs, but low levels of
secreted MMPs in most di¡erentiated tissues. However, at
early times in development numerous MPs are elevated,
with the exact proteases depending on the tissue, supporting
the hypothesis that MPs are high during active tissue gener-
ation, but low in stable tissue unless there is pathology. The
high levels of membrane-associated MPs may act to maintain
cells in an active state, awaiting substrates such as other pro-
teases or growth factors, while high expression of the TIMPs
may maintain tissue integrity. In addition, almost every pro-
teinase and inhibitor is present in the uterus or placenta dur-
ing gestation; mColA and mColB are found exclusively in the
uterus and testis ; and each tissue has its unique signature of
proteinase and inhibitor expression.
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